Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (606114)	8/26/2016 7:38:16 AM
From: skinowski	5 Recommendations Recommended By Alan Smithee alanrs D. Long MulhollandDrive Neeka Read Replies (2) \| Respond to of 793670

Jokichi Takamine first isolated epinephrine in 1901. [10] It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. [11] It is available as a generic medication. [1] The wholesale cost in the developing world is between US$0.10 and US$0.95 a vial. [12] In the United States an autoinjector for anaphylaxis, as of 2016, costs about US$600 for two. [13] en.m.wikipedia.org Actually, today's price is closer to $700, if not higher. Quite obviously, the transformation of one of the oldest and least costly medications into something fantastically expensive didn't happen due to free market forces.

To: Maurice Winn who wrote (606114)	8/26/2016 8:28:39 AM
From: DMaA	Respond to of 793670

The primary patent has expired. Now what is preventing competition is government regulations. So in effect they are charging what the government allows.